INBS
Intelligent Bio Solutions Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-59/100
Last price
1.65
▼ 0.02 (1.40%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.65
Prev close
1.67
Day high
1.81
Day low
1.57
Volume
97.12K
Market cap
$5.24M
P/E (TTM)
—
52W range
1.52 – 24.90
Day trading desk
Gap from prior close
-1.20%
Prior close 1.67
VWAP
1.60
+3.11% from price
Relative volume
1.19×
Normal
Session range
15.29%
1.57 – 1.81
Position in range
32%
Mid range
ATR (14D)
0.14
8.69% of price
Prior day high
1.70
PDH
Prior day low
1.65
PDL
Bid / ask spread
—
Quote not published
Session volume
193.16K
Avg 162.00K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.07%
-5.0%
1M
-29.15%
-30.3%
3M
-27.19%
-31.7%
6M
-41.04%
-59.2%
YTD
-83.42%
-97.7%
1Y
-86.50%
-102.9%
3Y
-98.72%
-181.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on INBS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
82.59K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 18, 26 | SAKIRIS SPIRO KEVIN Chief Financial Officer |
STOCK | 30.50K | $0 | Direct |
| Mar 18, 26 | HURD JONATHAN S Director |
STOCK | 5.00K | $0 | Direct |
| Mar 18, 26 | SIMEONIDIS HARRY Chief Executive Officer |
STOCK | 30.50K | $0 | Direct |
| Mar 18, 26 | BOYAGES STEVEN CONSTANTINE Director |
STOCK | 5.00K | $0 | Direct |
| Mar 18, 26 | ISENBERG JASON Director |
STOCK | 5.00K | $0 | Direct |
| Mar 18, 26 | FRASER NICOLA MARION Director |
STOCK | 5.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOYAGES STEVEN CONSTANTINE |
Director | 5.03K | Stock Award(Grant) |
FRASER NICOLA MARION |
Director | 5.00K | Stock Award(Grant) |
HURD JONATHAN S |
Director | 5.01K | Stock Award(Grant) |
ISENBERG JASON |
Director | 5.00K | Stock Award(Grant) |
SAKIRIS SPIRO KEVIN |
Chief Financial Officer | 35.89K | Stock Award(Grant) |
SIMEONIDIS HARRY |
Chief Executive Officer | 34.54K | Stock Award(Grant) |
Fundamentals
Market cap$5.24M
Enterprise value$2.24M
Revenue (TTM)$4.22M
Gross profit$2.05M
EBITDA$-11.15M
Net income$-12.43M
EPS (TTM)$-8.44
Free cash flow$-6.72M
Total cash$4.14M
Total debt$1.82M
Book value / share$1.90
Shares outstanding3.32M
Float2.94M
Short % of float3.71%
Dividend yield0.00%
Beta (5Y)4.30
Valuation & profitability ratios
Trailing P/E—
Forward P/E4.51
PEG ratio—
Price / sales—
Price / book0.83
EV / revenue0.53
EV / EBITDA-0.20
Gross margin48.63%
Operating margin-345.98%
Profit margin-294.91%
Return on equity-307.69%
Return on assets-76.20%
Debt / equity34.38
Current ratio1.44
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.22M | $3.05M | $3.11M | $1.26M | — | +38.1% |
| Operating revenue | $4.22M | $3.05M | $3.11M | $1.26M | — | +38.1% |
| Cost of revenue | $2.17M | $1.81M | $1.69M | $930.20K | — | +19.9% |
| Gross profit | $2.05M | $1.25M | $1.43M | $326.67K | — | +64.4% |
| Research & development | $3.37M | $2.40M | $1.67M | $507.42K | — | +40.7% |
| Selling, general & admin | $10.50M | $8.92M | $9.26M | $8.03M | — | +17.8% |
| Total operating expense | $14.36M | $11.71M | $11.71M | $8.76M | — | +22.7% |
| Operating income | -$12.31M | -$10.46M | -$10.28M | -$8.44M | — | -17.7% |
| Net interest income | $99.59K | $75.18K | -$82.32K | -$213.86K | — | +32.5% |
| Pre-tax income | -$12.47M | -$10.60M | -$10.19M | -$10.66M | — | -17.6% |
| Net income | -$12.43M | -$10.57M | -$10.16M | -$10.63M | — | -17.6% |
| Net income to common | -$12.43M | -$10.57M | -$10.16M | -$10.63M | — | -17.6% |
| Basic EPS | — | -20.04 | -63.80 | -1,270.00 | -1,368.00 | — |
| Diluted EPS | — | -20.04 | -63.80 | -1,270.00 | -1,368.00 | — |
| EBIT | -$12.46M | -$10.58M | -$10.02M | -$10.44M | — | -17.8% |
| EBITDA | -$11.29M | -$9.37M | -$8.81M | -$9.47M | — | -20.5% |
| Basic shares | — | 527.36K | 159.27K | 8.37K | 6.11K | — |
| Diluted shares | — | 527.36K | 159.27K | 8.37K | 6.11K | — |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.99M | $1.02M | $6.30M | $1.54M | +291.4% |
| Cash & short-term investments | $3.99M | $1.02M | $6.30M | $1.54M | +291.4% |
| Accounts receivable | $848.46K | $594.61K | $429.70K | $293.86K | +42.7% |
| Inventory | $418.58K | $635.22K | $777.54K | $979.91K | -34.1% |
| Total current assets | $7.10M | $4.14M | $8.53M | $3.86M | +71.5% |
| Property, plant & equipment | $2.05M | $320.85K | $872.59K | $1.24M | +537.5% |
| Goodwill & intangibles | $2.80M | $3.79M | $4.37M | $5.26M | -26.1% |
| Total assets | $11.94M | $8.25M | $13.78M | $10.35M | +44.8% |
| Total current liabilities | $4.93M | $5.35M | $5.45M | $5.88M | -7.9% |
| Current debt | — | $197.15K | $515.28K | $353.21K | — |
| Long-term debt | — | — | — | $402.86K | — |
| Total debt | $1.82M | $281.81K | $871.44K | $1.34M | +545.5% |
| Total liabilities | $6.65M | $5.44M | $5.60M | $6.67M | +22.4% |
| Retained earnings | -$74.96M | -$62.53M | -$51.96M | -$41.81M | -19.9% |
| Shareholder equity | $5.51M | $3.00M | $8.33M | $3.80M | +83.9% |
| Working capital | $2.17M | -$1.21M | $3.08M | -$2.02M | +278.8% |
| Net tangible assets | $2.71M | -$794.18K | $3.96M | -$1.46M | +441.4% |
| Shares issued | 2.91M | 732.34K | 345.60K | 19.42K | +296.8% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$12.47M | -$10.60M | -$10.19M | -$10.66M | -17.6% |
| Depreciation & amortisation | $1.16M | $1.21M | $1.21M | $966.73K | -3.6% |
| Stock-based compensation | $195.21K | $238.04K | $230.50K | $260.00K | -18.0% |
| Change in working capital | -$1.23M | -$720.78K | -$701.93K | $78.92K | -70.0% |
| Operating cash flow | -$11.93M | -$9.68M | -$9.57M | -$7.38M | -23.2% |
| Capital expenditure | -$125.73K | -$231.84K | -$221.43K | -$505.12K | +45.8% |
| Investing cash flow | -$85.57K | -$231.84K | -$221.43K | -$694.14K | +63.1% |
| Financing cash flow | $14.98M | $4.60M | $14.56M | $1.44M | +225.9% |
| Free cash flow | -$12.05M | -$9.91M | -$9.79M | -$7.88M | -21.6% |
| End cash position | $3.99M | $1.02M | $6.30M | $1.54M | +291.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.15M | $1.06M | $896.77K | $1.11M | $843.88K | — | +8.0% |
| Operating revenue | $1.15M | $1.06M | $896.77K | $1.11M | $843.88K | — | +8.0% |
| Cost of revenue | $609.22K | $525.42K | $437.04K | $593.51K | $508.31K | — | +15.9% |
| Gross profit | $536.58K | $535.38K | $459.74K | $518.29K | $335.58K | — | +0.2% |
| Research & development | $1.47M | $893.98K | $522.11K | $486.17K | $582.47K | — | +64.3% |
| Selling, general & admin | $2.99M | $2.46M | $2.34M | $2.66M | $2.72M | — | +21.6% |
| Total operating expense | $4.50M | $3.48M | $3.07M | $3.26M | $3.22M | — | +29.4% |
| Operating income | -$3.96M | -$2.94M | -$2.61M | -$2.74M | -$2.88M | — | -34.8% |
| Net interest income | $43.75K | $45.20K | -$50.88K | $4.60K | -$1.00K | — | -3.2% |
| Pre-tax income | -$3.92M | -$2.87M | -$2.69M | -$2.99M | -$3.10M | — | -36.5% |
| Net income | -$3.91M | -$2.86M | -$2.68M | -$2.98M | -$3.09M | — | -36.5% |
| Net income to common | -$3.91M | -$2.86M | -$2.68M | -$2.98M | -$3.09M | — | -36.5% |
| Basic EPS | — | -1.80 | -2.82 | -3.50 | — | -4.41 | — |
| Diluted EPS | — | -1.80 | -2.82 | -3.50 | — | -4.41 | — |
| EBIT | -$3.91M | -$2.87M | -$2.63M | -$2.99M | -$3.09M | — | -36.6% |
| EBITDA | -$3.63M | -$2.58M | -$2.35M | -$2.69M | -$2.79M | — | -40.8% |
| Basic shares | — | 1.59M | 950.83K | 854.69K | — | 577.19K | — |
| Diluted shares | — | 1.59M | 950.83K | 854.69K | — | 577.19K | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.99M | $6.86M | $740.37K | $1.66M | $1.02M | — | -41.8% |
| Cash & short-term investments | $3.99M | $6.86M | $740.37K | $1.66M | $1.02M | — | -41.8% |
| Accounts receivable | $848.46K | $878.36K | $456.66K | $717.82K | $594.61K | — | -3.4% |
| Inventory | $418.58K | $597.47K | $590.25K | $628.18K | $635.22K | — | -29.9% |
| Total current assets | $7.10M | $9.75M | $12.17M | $4.48M | $4.14M | — | -27.2% |
| Property, plant & equipment | $2.05M | $2.11M | $2.21M | $2.08M | $320.85K | — | -3.2% |
| Goodwill & intangibles | $2.80M | $3.00M | $3.27M | $3.47M | $3.79M | — | -6.7% |
| Total assets | $11.94M | $14.86M | $17.65M | $10.04M | $8.25M | — | -19.7% |
| Total current liabilities | $4.93M | $4.61M | $5.13M | $5.06M | $5.35M | — | +6.9% |
| Current debt | — | — | $13.00K | $139.79K | $197.15K | $356.16K | — |
| Total debt | $1.82M | $1.85M | $1.92M | $1.95M | $281.81K | — | -1.6% |
| Total liabilities | $6.65M | $6.11M | $6.76M | $6.61M | $5.44M | — | +8.8% |
| Retained earnings | -$74.96M | -$71.06M | -$68.19M | -$65.52M | -$62.53M | — | -5.5% |
| Shareholder equity | $5.51M | $8.96M | $11.09M | $3.62M | $3.00M | — | -38.5% |
| Working capital | $2.17M | $5.14M | $7.05M | -$577.71K | -$1.21M | — | -57.8% |
| Net tangible assets | $2.71M | $5.96M | $7.82M | $147.92K | -$794.18K | — | -54.5% |
| Shares issued | 2.91M | 2.00M | 1.24M | 909.85K | 732.34K | — | +45.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$3.92M | -$2.87M | -$2.69M | -$2.99M | -$3.10M | — | -36.5% |
| Depreciation & amortisation | $288.18K | $290.39K | $281.90K | $303.38K | $306.17K | — | -0.8% |
| Stock-based compensation | $97.43K | $24.20K | $61.58K | $12.00K | $12.00K | — | +302.5% |
| Change in working capital | $321.88K | -$1.71M | $736.95K | -$576.91K | $304.21K | — | +118.9% |
| Operating cash flow | -$3.18M | -$4.33M | -$1.57M | -$2.85M | -$2.21M | — | +26.5% |
| Capital expenditure | — | — | -$68.23K | -$70.40K | -$208.52K | -$14.38K | — |
| Investing cash flow | $0 | $12.90K | -$28.07K | -$70.40K | -$208.52K | — | -100.0% |
| Financing cash flow | $311.99K | $10.44M | $674.65K | $3.56M | $602.00K | — | -97.0% |
| Free cash flow | -$3.18M | -$4.32M | -$1.64M | -$2.92M | -$2.42M | — | +26.3% |
| End cash position | $3.99M | $6.86M | $740.37K | $1.66M | $1.02M | — | -41.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.58 | -0.90 | +43.0% |
| Mar 2026 | — | -1.80 | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.31 | 1 | $1.40M | — |
| Next quarter | -1.36 | 1 | $1.40M | — |
| Current year | -5.18 | 1 | $6.10M | +44.7% |
| Next year | -4.06 | 1 | $8.80M | +44.3% |
Analyst targets & ownership
Mean target$12.00
High target$12.00
Low target$12.00
Implied upside628.77%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders2.73%
Held by institutions5.47%
Institutions holding8
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.67
-1.40% from price
SMA 20
1.85
-14.39% from price
SMA 50
2.11
-24.98% from price
SMA 100
2.25
-26.96% from price
SMA 200
3.90
-59.44% from price
EMA 12
1.72
-4.54% from price
EMA 26
1.89
-12.86% from price
EMA 50
2.05
-19.65% from price
RSI (14)
29.1
Oversold
MACD (12,26,9)
-0.16
Hist -0.01
ATR (14)
0.14
9.06% of price
Realised vol 30D
46.7%
Annualised
Bollinger upper
2.25
20, 2σ
Bollinger lower
1.44
20, 2σ
50 / 200 cross
Death
2.11 vs 3.90
Trend bias
Below 200
-59.44%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.77
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
46.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-91.4%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.14
9.06% of price
Beta (reported)
4.30
5Y monthly, from filing
Short interest
Shares short
119.55K
Prior 105.07K
Change vs prior
+13.8%
Shorts adding
% of float
3.71%
Normal
% of shares out
3.60%
Against total outstanding
Days to cover
0.4
Liquid
Float
2.94M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:10
Split dateDec 16, 2025
SEC filings
Offering Registrations
S-3 · 2026-09-15
Additional Forms
D · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-09-01
Corporate Changes & Voting Matters
8-K · 2026-08-28
Periodic Financial Reports
10-K · 2026-08-19
Headlines
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
GlobeNewswire · 27d ago
Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market
Benzinga · 28d ago
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
GlobeNewswire · 28d ago
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
GlobeNewswire · 36d ago
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules
GlobeNewswire · 36d ago
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
GlobeNewswire · 49d ago
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
GlobeNewswire · 51d ago
Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
GlobeNewswire · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.